Bryan Norrie

Bryan Norrie



100 Murray Street
Suite 300
Ottawa, Ontario
K1N 0A1

Bryan Norrie is a partner at Aitken Klee LLP in the Ottawa office.

Bryan specializes in the litigation of pharmaceutical and biotechnology patents. He has a M.Sc. in Neuroscience and Biomedical Engineering, and is a registered Canadian patent agent. Bryan enjoys combining his technical and legal expertise to identify creative approaches to complex issues, and he has been ranked or recognized in many leading industry publications, where he has been hailed as a “strong litigator” and “exceptional lawyer” who “has tremendous experience”.

Bryan regularly appears in the Federal Court of Canada and Federal Court of Appeal in trials, application hearings, motions and appeals.

  • Bar Admission, Ontario – 2007
  • Registered Patent Agent, Canada – 2009


  • BCL/LLB 2006 – McGill University – with distinction
  • MSc 2003 (Neuroscience and Biomedical Engineering) – University of Alberta
  • BSc 2000 (Physiology, 1st class honours) – University of Alberta

Representative Work

Recent reported decisions:

Other recent notable litigation:

  • T-353-20 and T-1581-20 – Celgene v Natco (pomalidomide)
  • T-1187-19 – Bayer v Dr Reddy’s (rivaroxaban)
  • T-1527-18 and T-1529-18 – Celgene v Natco (lenalidomide)

Industry Recognition

  • Chambers and Partners (2021) – hailed by commentators as a “strong litigator” and an “exceptional lawyer.”
  • IAM Patent 1000 – ranked as one of the world’s leading patent practitioners (2015-2021) – “has tremendous experience
  • Legal 500 (Canada) – recognized as one of Canada’s leading intellectual property practitioners (2019)
  • Who’s Who Legal – Life Sciences 2021 (Patent Litigation)
  • Best Lawyers Global Business Edition 2020 (Intellectual Property Law)


Professional Affiliations

  • Intellectual Property Institute of Canada
  • Canadian Bar Association